Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in chinese population

Chinese Medical Journal

Volumn 125, Issue 5, 2012, Pages 741-746

  Zhang, Xiao Ping ^a   Bai, Zhi Bin ^a   Chen, Bao An ^a   Feng, Ji Feng ^b   Yan, Feng ^b   Jiang, Zhi ^b   Zhong, Yue Jiao ^b   Wu, Jian Zhong ^b   Chen, Lu ^a   Lu, Zu Hong ^a   Tong, Na ^c   Zhang, Zheng Dong ^c   Xu, Pei Pei ^a   Peng, Miao Xin ^a   Zhang, Wen Jing ^a   Wang, Shuai ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b Jiangsu Province Cancer Institute   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Dihydropyrimidine dehydrogenase; Fluorouracil; Gastric cancer; Single nucleotide polymorphisms

Indexed keywords

CAPECITABINE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GLIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMOTHERAPY, ADJUVANT; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863354408     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.05.004     Document Type: Article

References (14)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Macdonald JS. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004; 54: S4-S11.
3. Hejna M, Wöhrer S, Schmidinger M, Raderer M. Postoperative chemotherapy for gastric cancer. Oncologist 2006; 11: 136-145.
4. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
5. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530.
6. Yong Y, Lin HE. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-98.
7. Hasegawa T, Kim HS, Fukushima M, Wataya Y. Sequence analysis of the 5'-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil. Nucleosides Nucleotides Nucleic Acids 2005; 24: 233-242.
8. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12: 555-558.
9. Morel A, Boisdrom-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5: 2895-2904.
10. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 2006; 28: 678-685.
11. Magne N, Etienne-Grimaldi M-C, Cals L, Renée N, Formento JL, Francoual M, et al. Dihydropyrimidine dehydrogenase activity and IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Pharmacol 2007; 64: 237-240.
12. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol 2008; 26: 2131-2138.
13. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assenssment. Pharmacogenomics 2009; 10: 931-944.
14. Collie-Dugnid ES, Johnston SJ, Powrie RH, Milano G, Etienne MC, Rochat B, et al. Cloning and initial characterization of human DPYD gene promoter. Biochem Biophys Res Commun 2000; 271: 28-35.